The Mayo Clinic Center for Individualized Medicine is creating its Cancer/Normal Serum Biobank available to the researchers. Mayo is keenly eager to make cancer serum biobank available to research community.
Mayo attempted to extend availability of the biobank by itself but didn’t have the funds to properly market it, claims Stephen Thibodeau, PhD, director of the bio repositories program. Now, it has teamed with the iSpecimen, a human bio specimen collections vendor, to link the institution with outside research community. Now Mayo will soon make cancer serum biobank available to research community.
Serum is a proposed clear liquid, separated from clotted blood, utilized in blood typing and diagnostic tests, Thibodeau claims. Serum is very precious in the cancer research because it opens up a window into the body like waste materials, nutrients throughout the entire body, lipids, and carbohydrates “and everything required to operate the body,” he elaborates.
There will be a charge for the service but developing a profit is not a priority of the initiative, in accordance to Thibodeau. “We are attempting to capture the cost of what we are doing and not anxious about making money.”
The biobank has approximately 130,000 frozen vials of serum from over 17,000 consenting sufferers, gathered between the years of 1975 and 1990. The samples cover 85 distinctive non-tumors, malignant, malignant with no proof of disease, and benign conditions.
Under an outsourcing management, iSpecimen will handle the serum inventory and associated information through a cloud platform to match researchers to the correct samples. The platform surveys institutions for the availability of samples and connects investigators to an institution that has the desired samples. Investigators can inquire for a particular kind of serum or various different types.
No comments:
Post a Comment